There are currently 1875 clinical trials in Philadelphia, Pennsylvania looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Pennsylvania, Children's Hospital of Philadelphia, Fox Chase Cancer Center and Thomas Jefferson University. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of PBFT02 in Participants With FTD and Mutations in the Granulin Precursor (GRN) or C9ORF72 Genes
NCT04747431
Recruiting
PBFT02 is a gene therapy for frontotemporal dementia intended to deliver a functional copy of the GRN gene to the brain. This study will assess the safety, tolerability and efficacy of this treatment in patients with frontotemporal dementia and mutations in the granulin precursor (GRN) or chromosome 9 open reading frame 72 (C9ORF72) genes
Gender:
ALL
Ages:
Between 35 years and 75 years
Trial Updated:
01/21/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Frontotemporal Dementia, FTD, FTD-GRN, Dementia Frontotemporal, C9orf72
Register for Updates
"Embolization Before Ablation of Renal Cell Carcinoma (EMBARC)"
NCT05410509
Recruiting
Multi-center, single arm, prospective trial to estimate safety, feasibility, technical outcomes, and clinical outcomes of percutaneous cryoablation with neo-adjuvant trans-arterial embolization of the tumor in patients with T1b renal cell carcinoma. Continuous safety monitoring will be performed with stopping rules for patient accrual or study continuation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/21/2025
Locations: Thomas Jefferson Health, Philadelphia, Pennsylvania
Conditions: Renal Cell Carcinoma (RCC)
Register for Updates
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
NCT05734066
Recruiting
This study is conducted in two phases. The phase 1 portion of the study evaluates the safety, tolerability, pharmacokinetics (PK), recommended phase 2 dose (RP2D), and effectiveness of lurbinectedin monotherapy in pediatric participants with previously treated solid tumors. This is followed by the phase 2 portion, to further assess the effectiveness and safety in pediatric and young adult participants with recurrent/refractory Ewing sarcoma.
Gender:
ALL
Ages:
Between 2 years and 30 years
Trial Updated:
01/21/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma, Ewing Sarcoma
Register for Updates
Treatment of Mycosis Fungoides with Hypericin Ointment and Visible Light
NCT05872854
Recruiting
The goal of this clinical trial is to assess the benefit of continuous treatment with synthetic hypericin ointment (HyBryte) and visible light in patients with mycosis fungoides for up to 12 months (54 weeks). Funding Source: FDA OOPD.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/21/2025
Locations: Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania
Conditions: Cutaneous T Cell Lymphoma, Mycosis Fungoides
Register for Updates
A Study with L19TNF in Combination with Lomustine in Patients with Glioblastoma At Progression or Recurrence
NCT06336291
Recruiting
The trial aims to collect safety, efficacy, exposure, dose- response, pharmacokinetic and pharmacodynamic information of the combination of L19TNF and lomustine at different dose levels in patients with Glioblastoma at progression or recurrence
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/21/2025
Locations: Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Glioblastoma
Register for Updates
Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy
NCT04691817
Recruiting
This is a research study to evaluate the safety and effectiveness of tocilizumab in combination with atezolizumab to treat non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/20/2025
Locations: Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Lung Cancer, Nonsmall Cell
Register for Updates
Assessment of Chronic Lung Allograft Dysfunction Using Single-breath & Multi-breath Hyperpolarized Xenon-129 MRI
NCT04941573
Recruiting
This study will use Magnetic Resonance Imaging (MRI) to study the lungs of 90 volunteers using the inhaled contrast agent, hyperpolarized xenon-129. Once inhaled, this gas can provide information to imagers regarding lung functionality across specific regions of the lungs by assessing the replacement of air during the normal breathing cycle, how much oxygen is in the airspaces, and if the natural spongy tissue structure has been compromised by lung disease. Of the 90 subjects, 70 will be patient... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/17/2025
Locations: Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Lung Transplant Rejection
Register for Updates
Parathyroid Tumor Clonal Status
NCT05997810
Recruiting
To define the frequency of monoclonal-X and polyclonal-X tumors in PHPT participants having parathyroidectomy (PTX) and to define the relationship between parathyroid tumor clonal status and multiple gland neoplasia (MGN), we will compare surgical and pathologic outcomes to tumor clonal status in a multicenter cohort of patients having bilateral neck exploration (BNE) and PTX (primary objectives).
Gender:
FEMALE
Ages:
Between 18 years and 80 years
Trial Updated:
01/17/2025
Locations: Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Parathyroid Tumor, Primary Hyperparathyroidism
Register for Updates
Liquid Biopsy in Ewing Sarcoma and Osteosarcoma As a Prognostic and Response Diagnostic: LEOPARD
NCT06068075
Recruiting
This is a prospective multicenter biomarker study evaluating the prognostic impact of ctDNA detection at diagnosis in patients with Ewing sarcoma or osteosarcoma.
Gender:
ALL
Ages:
Between 12 months and 50 years
Trial Updated:
01/17/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Ewing Sarcoma, Ewing Sarcoma of Bone, Ewing Sarcoma of Soft Tissue, Peripheral Primitive Neuroectodermal Tumor, Peripheral Primitive Neuroectodermal Tumor of Bone, Peripheral Primitive Neuroectodermal Tumor of Soft Tissue, High-grade Osteosarcoma
Register for Updates
Functional and Structural Assessment of Endobronchial Valve Recipients Using Dynamic Hyperpolarized Xenon-129 MRI
NCT05433961
Recruiting
This study proposes to use hyperpolarized xenon-129 Magnetic Resonance Imaging (MRI) to study lung function of COPD patients who will receive endobronchial valve (EBV) therapy as part of their clinical standard-of-care. Once inhaled, HP xenon can provide information to imagers regarding functionality across specific regions of the lungs through the assessment of the replacement of air during the normal breathing cycle, how much oxygen is in the airspaces, and if the normal spongy tissue structur... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
01/16/2025
Locations: Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: COPD
Register for Updates
Topical Anti-Androgens in Pilonidal Sinus Disease
NCT06286397
Recruiting
The goal of this randomized clinical trial is to test the topical drug clascoterone in patients with pilonidal disease, which is a common, benign skin condition of the gluteal cleft. The main questions it aims to answer are: * Does clascoterone improve the severity of pilonidal disease as scored by a physician? * Does clascoterone improve patient symptoms due to pilonidal disease? * Does clascoterone improve the inflammation seen under the microscope in pilonidal disease removed at surgery Part... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Pilonidal Disease, Pilonidal Disease of Natal Cleft, Pilonidal Sinus, Pilonidal Cyst
Register for Updates
PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC
NCT06366451
Recruiting
This is a multi-center, open-label, Phase 0 substudy designed to evaluate the localized pharmacodynamics (PD) of rilvegostomig, volrustomig, sabestomig, and AZD9592 within the tumor microenvironment (TME) when administered intratumorally in microdose quantities via the CIVO device in patients presenting with Head and Neck Squamous Cell Carcinoma (HNSCC) with a surface accessible lesion, who are scheduled for tumor and/or regional node dissection as part of their standard treatment. PD effects du... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Head and Neck Squamous Cell Carcinoma
Register for Updates